Does Insurance Cover Zepbound or Wegovy? How to Check in 2026

Commercial plans that have opted into weight-loss drug coverage are the ones that cover Zepbound and Wegovy, usually with prior authorization. UnitedHealthcare describes its weight-loss prior authorization as "an optional program" for clients that have elected to cover weight-loss products.1 Cigna's coverage policies state that a customer's own benefit plan document always overrides the policy, and that a plan may contain a specific exclusion.2

That means "is Zepbound covered by insurance" has three possible answers for any one person:

1. Covered for weight loss. Your plan includes weight-loss drugs and the drug is on its formulary, normally with prior authorization.
2. Covered for another condition only. The plan excludes weight-loss drugs but covers a GLP-1 for an approved non-weight use, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea.1
3. Not covered. The plan excludes the drug, or its pharmacy benefit manager prefers a competitor.

The third case is common. CVS Caremark removed Zepbound from its commercial template formularies and made Wegovy the preferred drug from July 1, 2025; members can request a formulary exception if Wegovy caused intolerable side effects or did not work.4

The table lists only what we could verify from each insurer's or program's own documents. Where we could not find a published national policy, we say so rather than guess.

UnitedHealthcare covers Zepbound and Wegovy only if your employer elected its weight-loss program. Under that program, effective October 1, 2026, initial approval requires a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, dyslipidemia, type 2 diabetes or sleep apnea, and use alongside lifestyle changes.1 Zepbound is first approved for 6 months and Wegovy for 5 months; renewal for Wegovy requires at least 5% weight loss from baseline, or that you are still titrating within your first six months.1

Aetna's coverage depends on the formulary your plan uses. On the Aetna Standard Plan formulary, Zepbound was added and Foundayo moved from non-preferred to preferred effective October 1, 2026.3 Whether that helps you still depends on whether your plan includes weight-loss drugs; your member website shows your formulary and estimated cost.3

Cigna requires prior authorization for its GLP-1 weight-loss drugs, and your benefit plan document overrides Cigna's coverage policy if the two conflict.2 Its Foundayo policy, effective September 1, 2026, illustrates the typical criteria: age 18 or older, at least 3 months of behavioral and dietary change, and a baseline BMI of 30 or more, or 27 or more with a weight-related condition.2 Wegovy and Zepbound have their own Cigna policies, and the criteria your plan uses can differ.

There is no single Blue Cross Blue Shield answer. The Blue Cross Blue Shield Association is made up of 33 independent, locally operated companies, and each sets its own formularies and coverage rules.6 Anthem plans and Kaiser Permanente plans also set coverage by plan and region. For any of these, look up your plan's formulary on the member site or call the number on your card.

Yes for some TRICARE plans, no for others. TRICARE covers Wegovy, Saxenda and Zepbound for weight management under TRICARE Prime, Prime Remote, US Family Health Plan, Select, Young Adult, Reserve Select, Retired Reserve and the Continued Health Care Benefit Program, subject to clinical criteria and prior authorization.5 It does not cover weight-loss drugs for TRICARE For Life beneficiaries or people with direct-care-only coverage.5 TRICARE notes that from July 1, 2026, Medicare Part D covers certain weight-loss drugs through the Medicare GLP-1 Bridge.5

It may, even when your plan excludes weight-loss drugs. Zepbound has been FDA approved for moderate to severe obstructive sleep apnea in adults with obesity since December 2024, which makes it a treatment for a medical condition rather than only a weight-loss drug.7 UnitedHealthcare lists sleep apnea as an approved reason for Zepbound and refers plans that do not cover weight-loss medications to separate non-formulary Zepbound criteria.1

Public programs follow the same logic. State Medicaid programs must cover Zepbound for sleep apnea and Wegovy for cardiovascular disease, while covering them for weight loss alone is optional for each state.7 Medicare Part D plans may cover GLP-1s for type 2 diabetes or moderate-to-severe sleep apnea, and people with those conditions are excluded from the Medicare GLP-1 Bridge for that reason.8 Our Medicare GLP-1 coverage guide covers this in detail.

Expect the plan to ask for a sleep study confirming the diagnosis and severity. Your prescriber's office handles that paperwork.

Start by confirming the benefit, then build the prior authorization around the plan's own criteria.

1. Check the formulary. Search your plan's drug list for Zepbound, Wegovy and Foundayo. Note the tier and any "PA" (prior authorization), "ST" (step therapy) or "QL" (quantity limit) codes.
2. Ask whether weight-loss drugs are a covered benefit. If the plan excludes the category, a prior authorization for weight loss will be denied whatever your BMI. A covered non-weight indication, such as sleep apnea or cardiovascular disease, is a separate route.1,7
3. Get the criteria in writing. Most plans publish them. Typical requirements are a BMI threshold, documented comorbidities and a record of diet and exercise.1,2
4. Have your prescriber submit the prior authorization with chart notes showing each criterion is met.
5. Plan for renewal. Many plans re-check weight loss after the first approval period, for example at least 5% for Wegovy under UnitedHealthcare.1
6. If denied, appeal. Ask for the denial reason in writing. If your PBM prefers a competitor, a formulary exception with documented side effects or lack of response on the preferred drug is the usual route.4

Once covered, the manufacturer cards lower your copay. Lilly's Zepbound card can bring a covered fill to as little as $25, capped at $100 off a month and $1,300 a year.9 Novo Nordisk's Wegovy offer is as little as $25 a month, with a maximum saving of $100 a month.10 Both exclude people on government insurance.9,10 Details are in our Zepbound savings card guide.

If your plan will not cover Zepbound or Wegovy, the manufacturers' self-pay prices are the main alternative. As of October 2026 Zepbound KwikPen and vials start at $299 a month, and Wegovy pens are $349 a month after an introductory offer.9,10 Our GLP-1 cost without insurance guide compares every option, and our Wegovy vs Zepbound comparison helps if your plan prefers one over the other.

Is Zepbound covered by insurance for weight loss? Only if your plan includes weight-loss drugs and lists Zepbound on its formulary. Some PBMs, including CVS Caremark, prefer Wegovy instead.4

Why does my friend with the same insurer have coverage when I don't? Employers choose whether to buy the weight-loss benefit. UnitedHealthcare describes its program as optional for clients that elect it.1

Does insurance cover Wegovy for heart disease? Plans that exclude weight-loss drugs may still cover Wegovy for cardiovascular risk reduction in people with established cardiovascular disease, and state Medicaid programs must cover that use.1,7

Does TRICARE For Life cover Zepbound? No. TRICARE does not cover weight-loss drugs for TRICARE For Life beneficiaries.5

How long does prior authorization last? It varies by plan. Under UnitedHealthcare's program, initial approval is 6 months for Zepbound and 5 months for Wegovy, and renewals last 12 months.1

Compare programs side by side in our GLP-1 program ranking, then check current prices on the Zepbound cost and Wegovy cost pages.

This article is for information only and is not medical, legal or financial advice. Coverage is set by your plan document and can change at any time. Confirm your benefits with your insurer and talk to a licensed clinician before starting any medication.